Crohn's Disease Treatment Market Anticipated To Grow Steadily, Supported By Demand Drivers And Key Industry Trends.
The crohn's disease treatment market size is expected to see strong growth in the next few years. It will grow to $18.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to pipeline expansion of biologics and small molecules, rising demand for personalized treatment, growth of online pharmacy penetration, increasing healthcare expenditure in emerging markets, long-term disease management focus. Major trends in the forecast period include rising adoption of biologic therapies, shift toward early and aggressive treatment approaches, increasing focus on steroid-sparing regimens, growth of oral small-molecule therapies, expansion of online and specialty pharmacy channels.
Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10852&type=smp
Which Major Drivers Are Strengthening Demand In The Crohn's Disease Treatment Market?
The increase in the prevalence of inflammatory bowel disorders is expected to propel the growth of the Crohn's disease treatment market going forward. Inflammatory bowel disorders refer to a group of chronic conditions involving gastrointestinal tract inflammation. It can cause inflammation and damage to any part of the digestive system, from the mouth to the anus. Crohn's disease helps by decreasing the inflammation of the intestine, to prevent flare-ups of symptoms, and to keep in remission. For instance, in September 2023, according to the National Center for Biotechnology Information, a US-based government organization, the prevalence of Crohn’s disease and ulcerative colitis has similarly increased, with inflammatory bowel disease projected at 825 cases per 100,000 people in 2023, 410 for Crohn’s disease and 414 for ulcerative colitis and IBD-u. As a result, the rising prevalence of these disorders is fueling the expansion of the Crohn's disease treatment market.
How Is The Crohn's Disease Treatment Market Divided Across Its Major Segment Categories?
The crohn's disease treatment market covered in this report is segmented –
1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Neuropathic Pain, Fibromyalgia, Chronic Back Pain, Arthritic Pain, Migraine Post-Operative Pain, Cancer Pain, Other Applications
Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Other Antibiotics
2) By Amino Salicylates: Mesalamine, Sulfasalazine, Other Amino Salicylates
3) By Corticosteroids: Prednisone, Budesonide, Other Corticosteroids
4) By Immunomodulators: Azathioprine, Methotrexate, Mercaptopurine
5) By Other Drug Types: Biologics, Small Molecules, Other Treatments
What Trends Are Driving Change Across The Crohn's Disease Treatment Market Landscape?
Major companies operating in the crohn’s disease treatment market are innovating new drugs and getting them approved, such as biosimilar ustekinumab, to provide more effective and accessible treatment options for patients, ultimately improving patient outcomes and quality of life. Biosimilar ustekinumab refers to a biologic drug highly similar to the original ustekinumab (a monoclonal antibody) used for treating autoimmune conditions. For instance, in July 2024, Sandoz International GmbH, a Switzerland-based pharmaceutical company, launched Pyzchiva (ustekinumab) across Europe, marking it as the first ustekinumab biosimilar available in all strengths, including a 130 mg vial specifically for Crohn’s disease. This product is indicated for adults and children over six with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, enhancing Sandoz's immunology portfolio while aiming to improve access to affordable treatments for chronic inflammatory disease.
Which Influential Players Dominate The Competitive Environment Of The Crohn's Disease Treatment Market?
Major companies operating in the crohn's disease treatment market are AbbVie Inc., Janssen Pharmaceuticals, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Galapagos NV, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals, Tillotts Pharma AG, Dr. Falk Pharma GmbH, Shire Pharmaceuticals, Salix Pharmaceuticals, Prometheus Laboratories Inc., Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd.
Get Your In-Depth Crohn's Disease Treatment Market Report Now:
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Which Geographic Markets Are Contributing Most Significantly To The Progress Of The Crohn's Disease Treatment Market?
North America was the largest region in the global Crohn's disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crohn's disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Contact Us:#
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment